Alkermes Plc (NASDAQ:ALKS) Director Paul J. Mitchell sold 1,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $54.99, for a total transaction of $54,990.00. Following the completion of the sale, the director now directly owns 9,000 shares of the company’s stock, valued at approximately $494,910. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Alkermes Plc (NASDAQ ALKS) traded up $0.66 during mid-day trading on Wednesday, hitting $55.88. 501,181 shares of the stock were exchanged, compared to its average volume of 542,800. Alkermes Plc has a twelve month low of $46.42 and a twelve month high of $63.40. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.05 and a quick ratio of 2.72. The firm has a market capitalization of $8,590.00, a P/E ratio of -50.34 and a beta of 2.13.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Thursday, October 26th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.04. Alkermes had a negative net margin of 20.12% and a negative return on equity of 7.27%. The business had revenue of $217.40 million during the quarter, compared to the consensus estimate of $231.29 million. During the same quarter last year, the company earned ($0.09) earnings per share. The business’s quarterly revenue was up 20.6% compared to the same quarter last year. research analysts forecast that Alkermes Plc will post -0.59 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the company. FMR LLC grew its position in shares of Alkermes by 0.4% during the second quarter. FMR LLC now owns 22,978,575 shares of the company’s stock worth $1,332,068,000 after buying an additional 96,457 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Alkermes by 3.7% during the second quarter. Vanguard Group Inc. now owns 12,546,198 shares of the company’s stock worth $727,303,000 after buying an additional 449,563 shares in the last quarter. Woodford Investment Management Ltd grew its position in shares of Alkermes by 2.4% during the second quarter. Woodford Investment Management Ltd now owns 7,647,977 shares of the company’s stock worth $443,353,000 after buying an additional 177,449 shares in the last quarter. Thornburg Investment Management Inc. grew its position in shares of Alkermes by 39.8% during the third quarter. Thornburg Investment Management Inc. now owns 2,779,364 shares of the company’s stock worth $141,303,000 after buying an additional 790,692 shares in the last quarter. Finally, Janus Henderson Group PLC grew its position in shares of Alkermes by 13.7% during the third quarter. Janus Henderson Group PLC now owns 2,650,006 shares of the company’s stock worth $134,726,000 after buying an additional 319,014 shares in the last quarter. 99.17% of the stock is owned by institutional investors and hedge funds.

Several analysts have issued reports on ALKS shares. UBS Group set a $54.00 price objective on shares of Alkermes and gave the company a “hold” rating in a research report on Friday, October 27th. Mizuho set a $81.00 price objective on shares of Alkermes and gave the company a “buy” rating in a research report on Saturday, October 21st. Credit Suisse Group set a $66.00 price objective on shares of Alkermes and gave the company a “buy” rating in a research report on Tuesday, November 28th. BidaskClub raised shares of Alkermes from a “sell” rating to a “hold” rating in a research report on Wednesday, December 27th. Finally, ValuEngine raised shares of Alkermes from a “sell” rating to a “hold” rating in a research report on Friday, December 1st. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Alkermes has an average rating of “Hold” and a consensus target price of $63.55.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/03/insider-selling-alkermes-plc-alks-director-sells-1000-shares-of-stock.html.

About Alkermes

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.